Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells $63,236.60 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Xenon Pharmaceuticals Trading Down 2.7%

NASDAQ:XENE opened at $51.34 on Thursday. The firm has a market cap of $4.96 billion, a PE ratio of -10.92 and a beta of 0.62. The stock has a fifty day moving average price of $55.63 and a 200 day moving average price of $48.85. Xenon Pharmaceuticals Inc. has a 12-month low of $30.00 and a 12-month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the business earned ($0.83) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Neo Ivy Capital Management purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter worth about $2,001,000. JPMorgan Chase & Co. lifted its holdings in Xenon Pharmaceuticals by 11.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock worth $56,171,000 after buying an additional 142,452 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Xenon Pharmaceuticals during the 4th quarter worth about $5,342,000. HighVista Strategies LLC increased its position in shares of Xenon Pharmaceuticals by 80.2% during the third quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock worth $3,300,000 after purchasing an additional 36,570 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $7,837,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on XENE shares. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a report on Monday, March 9th. Royal Bank Of Canada lifted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Robert W. Baird lifted their target price on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Needham & Company LLC decreased their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.